Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01645241 |
Recruitment Status
:
Completed
First Posted
: July 20, 2012
Last Update Posted
: October 27, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
INFERTILITY Fertility Preservation Ovulation Induction Vitrification Oocyte Donation | Drug: gonadotropins plus GnRH antagonists Drug: ganirelix | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 15 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation |
Study Start Date : | July 2012 |
Actual Primary Completion Date : | December 2013 |
Actual Study Completion Date : | December 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: Lutheal phase ovarian stimulation
Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
|
Drug: gonadotropins plus GnRH antagonists
Other Name: Ovarian stimulation
Drug: ganirelix
Other Name: the investigators will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix
|
- Pregnancy rate [ Time Frame: six weeks after transfer procedure ]
- Number of Mature oocytes [ Time Frame: Day of oocyte retrieval ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- premenopausal women, 18-35 years old, FSH levels < 10 mIU/ml; AFC> 10
- regular cycles
- BMI < 28
- signed informed consent
Recipients:
- Infertile women eligible for oocytes donation
- BMI < 35
- Signed informed consent form
Exclusion Criteria:
-Polycystic ovarian syndrome, gonadotropins allergy
Recipients:
- Women eligible for oocytes donation
- BMI >35
- Uncontrolled Endocrine Pathology

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01645241
Spain | |
Departamento de Obstetricia Ginecologia y Reproducción. Institut Universitari Dexeus | |
Barcelona, Spain, 08037 |
Principal Investigator: | Francisca Martínez, PhD | Fundación Dexeus Salut de la Dona |
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT01645241 History of Changes |
Other Study ID Numbers: |
DEX005 |
First Posted: | July 20, 2012 Key Record Dates |
Last Update Posted: | October 27, 2014 |
Last Verified: | March 2013 |
Keywords provided by Institut Universitari Dexeus:
Ovarian stimulation Luteal phase Egg donors Fertility preservation |
Additional relevant MeSH terms:
Infertility Genital Diseases, Male Genital Diseases, Female Ganirelix |
Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |